Innovent Biologics has secured a $1 billion licensing agreement with Roche for the development of IBI3009, a DLL3-targeted antibody-drug conjugate aimed at advanced small cell lung cancer. The deal includes an $80 million upfront payment, with potential milestone payments and royalties based on sales. IBI3009, developed using Innovent's TOPO1i platform, has shown promising anti-tumor activity and a favorable safety profile in preclinical studies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.